FDA fast track designation was granted for ETX-19477 in BRCA-mutated HR+/HER2– unresectable or metastatic breast cancer, ...

Agentic AI streamlines oncology decisions and trial matching, cutting admin load, flagging care gaps, and widening community ...

David Savage, MD, PhD, discusses the significance of abemaciclib's PFS benefit in liposarcoma and how he approaches getting ...

While the survival advantage seen among Asian American women with breast cancer isn't yet ready to shape clinical practice ...

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how real-world practice for preventing febrile neutropenia in extensive-stage small cell lung cancer often runs ahead ...

City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non ...

FDA CBER Type C meeting will scrutinize statistical justification for pooled nonconcurrent published controls versus OST-400 ...

Maureen Cox, PhD, and Jumana Abbadi, MD, explain how macrophage-derived BDNF drives sensory nerve growth into triple-negative ...

Patrick Borgen, MD, built Brooklyn's breast cancer program from 47 patients to 8,000. Now he and Joshua Feinberg, MD discuss ...

HR-positive disease accounts for approximately 70% to 80% of breast cancer diagnoses and carries a risk of recurrence that ...

Hormone receptor and HER2 assessment remains the cornerstone for breast cancer subtyping and initial systemic therapy ...

Real-world ASCO 2026 data show ePRO-based remote monitoring helps catch metastatic cancer treatment symptoms earlier, ...